Total Funding
55
49
Total FundingPost-IPO Equity raised
Growth Score
-2 pts
Heat Score
-4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
72254
Adverum Biotechnologies is a gene therapy company that focuses on developing medicines that can offer therapeutic benefits to patients.
- Mark S. Blumenkranz: Founder & Director
Mitchell Finer: Founder & Senior ConsultantPast Role: Oncorus, Chief Executive Officer & Chief Scientific Officer
Eli Lilly
About the Company
Adverum Biotechnologies is a clinical-stage company that aims to establish gene therapy as a new standard of care for a number of highly prevalent ocular diseases with the aspiration of developing functional cures for these diseases to restore vision and prevent blindness. Their services include gene therapy, biotechnology, rare diseases,
ophthalmology, and retina.
